Exacerbation of Acute Pancreatitis in the Presence of Chronic Liver Injury in Rats, with Special Reference to Therapeutic Efficacy of Prostaglandin E1

Takahashi, Hiroki; Imamura, Mikio; Mikami, Yukio; Yamauchi, Hidemi

doi:10.1097/00006676-199908000-00014

Cited by 9 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33 A number of scholars pointed out that PGE1 can reduce CRP level in patients with systemic sclerosis, 34 hs-CRP level in patients undergoing percutaneous coronary intervention, 35 and CRP in a mouse model of chronic liver injury with acute pancreatitis. 36 Thus, the results of the present study (a significant decline in hs-CRP level after 2 weeks of treatment with lipo-PGE1) are consistent with previous observations related to PGE1 effects on patients with other diseases. Nevertheless, in this study, there was no significant difference in hs-CRP level between the groups after 2 weeks of treatment, which may be due to the use of an insufficient dose of lipo-PGE1, a short treatment course or the small sample size.…”

Section: Ta B L Esupporting

confidence: 93%

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Wang

Tang

Xie

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

Social and healthcare improvements have prolonged individuals' lifespan worldwide, while they have resulted in an increased number of patients with end-stage renal disease (ESRD). 1 Peritoneal dialysis (PD) is extensively applied in the treatment of ESRD, with comparable outcomes to hemodialysis, including preservation of residual renal function, 2 being cost-effective, and higher quality of life. 3 In recent years, PD utilization has greatly attracted clinicians' attention in China, and over 250,000 patients have received PD according to the statistics reported in 2012. 4 However, peritoneal transport function gradually diminishes with the extended use of PD, and can eventually lead to ultrafiltration failure. [5][6][7] The dialysate/plasma creatinine ratio (D/Pcr) and the mass transfer area coefficient (MTAC) for urea (MTAC-urea) and creatinine (MTAC-creatinine) are commonly used indicators to assess peritoneal transport of small molecular solutes. 8 A specific correlation was reported between D/Pcr and MTAC-creatinine, and a change in MTAC can influence the effective peritoneal surface area. 9 In addition to the transport of creatinine and other small molecular

show abstract

Section: Ta B L Esupporting

confidence: 93%

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Wang

Tang

Xie

et al. 2021

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…In addition, exocrine pancreatic function has been reported to be damaged in chronic liver disease [27] and chronic viral hepatitis [28] . An animal study showed exacerbation of acute pancreatitis in the presence of chronic liver injury in rats [29] . On the other hand, pancreatogenic diabetes, regarded as a form of "secondary diabetes" [30] , accounts for 1% to 2% of all diabetic patients in North America but as many as 15% to 20% of diabetic patients in the Southeast Asian continents [31] .…”

Section: Impact Of Liver Diseases On β Cell Dysfunctionmentioning

confidence: 99%

Impact of liver diseases on the development of type 2 diabetes mellitus

Hsieh¹,

Hsieh²

2011

WJG

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) is higher in patients who have liver diseases such as nonalcoholic fatty liver disease, chronic viral hepatitis, hemochromatosis, alcoholic liver disease and cirrhosis. It is suggested that there is a pathogenic link between the presence of T2DM and the severity of liver injury. However, evidence related to the impact of hepatic inflammation on the development of T2DM has not yet emerged. This article provides an overview of the evidence for an increased prevalence of diabetes in a range of liver diseases, the impact of liver diseases on insulin resistance and β cell dysfunction, and the potential mechanisms whereby coexistent liver diseases exacerbate the development of T2DM.

show abstract

“…In addition, exocrine pancreatic function has been reported to be damaged in chronic liver disease [9] and chronic viral hepatitis [10]. Animal study showed exacerbation of acute pancreatitis in the presence of chronic liver injury in rats [11]. However, whether or not the pancreatic insulin secretion is impaired in the development of portal-endotoxaemiainduced chronic hepatic inflammation is not elucidated.…”

Section: Introductionmentioning

confidence: 99%

Mild portal endotoxaemia induces subacute hepatic inflammation and pancreatic β‐cell dysfunction in rats

Chan

Shyu

et al. 2008

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Exacerbation of Acute Pancreatitis in the Presence of Chronic Liver Injury in Rats, with Special Reference to Therapeutic Efficacy of Prostaglandin E1

Cited by 9 publications

References 0 publications

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Lipid microsphere‐coated PGE1 improves peritoneal transport and reduces inflammation in peritoneal dialysis: A randomized clinical pilot trial

Impact of liver diseases on the development of type 2 diabetes mellitus

Mild portal endotoxaemia induces subacute hepatic inflammation and pancreatic β‐cell dysfunction in rats

Contact Info

Product

Resources

About